ストックスクリーナーアプリを入手
14.19
5.19%
0.70
プレマーケット:
14.79
0.60
+4.23%
前日終値:
$13.49
開ける：
$13.78
24時間の取引高:
80,867
Relative Volume:
1.17
時価総額：
$205.41M
収益：
$1.80M
当期純損益:
$-241.36M
株価収益率:
-2.7715
EPS:
-5.12
ネットキャッシュフロー:
$-197.90M
1週間 パフォーマンス:
+11.38%
1か月 パフォーマンス:
-2.81%
6か月 パフォーマンス:
+10.17%
1年 パフォーマンス:
-57.97%
1日の値動き範囲:
$13.40
$14.37
1週間の範囲:
$12.51
$14.86
52週間の値動き範囲:
$10.80
$39.79
Inhibrx Biosciences Inc Stock (INBX) Company Profile
名前
Inhibrx Biosciences Inc
セクター
電話
(858) 795-4220
住所
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
INBX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
14.19 | 205.41M | 1.80M | -241.36M | -197.90M | -5.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-23 | 開始されました | JMP Securities | Mkt Perform |
| 2024-01-23 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | 開始されました | SMBC Nikko | Outperform |
| 2021-09-21 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-09-14 | 開始されました | Credit Suisse | Outperform |
| 2020-09-14 | 開始されました | Evercore ISI | Outperform |
すべてを表示
Inhibrx Biosciences Inc (INBX) 最新ニュース
Inhibrx's Ozekibart Shows Promising 40% Response Rate in Advanced Colorectal Cancer Trial - StockTitan
How to Take Advantage of moves in (INBX) - Stock Traders Daily
Inhibrx Biosciences enters $150M loan facility - MSN
Inhibrx Biosciences, Inc. Announces Loan Agreement with Oxford Finance LLC - Marketscreener.com
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance - StreetInsider.com
Inhibrx Secures $150M Financing Deal to Advance Clinical Programs, Receives $100M Upfront - StockTitan
(INBX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
How To Trade (INBX) - Stock Traders Daily
Inhibrx's SWOT analysis: biotech stock faces pivotal year amid clinical trials - Investing.com India
(INBX) Trading Report - Stock Traders Daily
Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year By Investing.com - Investing.com Nigeria
Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com
2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy - News & Insights
Inhibrx Biosciences director Jon Faiz Kayyem buys $1.52m in stock - Investing.com Nigeria
Trend Tracker for (INBX) - Stock Traders Daily
The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares - Yahoo Finance
institutional investors of Inhibrx Biosciences, Inc. (NASDAQ:INBX) must be disappointed after last week's 15% drop - Simply Wall St
Perceptive Advisors LLC Bolsters Stake in Inhibrx Biosciences Inc - GuruFocus.com
Inhibrx Biosciences Inc (INBX) Quarterly 10-Q Report - Quartzy
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PR Newswire
Inhibrx Q3 Loss Narrows to $2.84/Share, Maintains $196M Cash for Clinical Programs - StockTitan
Inhibrx Biosciences Inc. (INBX) Quarterly 10-Q Report - Quartzy
Wilson Sonsini Knocks Out Claims Against Inhibrx Biosciences in Trade Secrets Verdict - Law.com
Inhibrx Biosciences’ Trade Secret Case - Global Legal Chronicle
(INBX) Trading Signals - Stock Traders Daily
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation - Financial Times
James Sabry on industry-shaping changes in innovation and deal-making - BioCentury
Long Term Trading Analysis for (INBX) - Stock Traders Daily
Inhibrx Biosciences' SWOT analysis: cash-rich biotech stock faces pivotal year - Investing.com Australia
Inhibrx Biosciences' SWOT analysis: cash-rich biotech stock faces pivotal year By Investing.com - Investing.com South Africa
why ImmunityBio Inc [IBRX] is a Good Choice for Investors After New Price Target of $6.38 - The DBT News
INVX underperforms with a -2.86 decrease in share price - US Post News
You might want to take a look at Imunon Inc (IMNN) now - SETE News
Immuneering Corp [IMRX] Shares Fall Approximately -71.25% Over the Year - Knox Daily
ImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Private Advisor Group LLC - Defense World
Incyte (NASDAQ:INCY) Given “Hold” Rating at Truist Financial - Defense World
Inhibrx, Inc. (NASDAQ:INBX) Short Interest Down 6.9% in August - Defense World
InnovAge (NASDAQ:INNV) Trading Up 4.2% - Defense World
William Hoffman Sells 40,000 Shares of Inari Medical, Inc. (NASDAQ:NARI) Stock - Defense World
INmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interest - Defense World
INmune Bio stock remains a Buy with positive data correlation in Alzheimer’s study, says Scotiabank - Investing.com
A review of IMNN’s current quarter earnings predictions - US Post News
Its Stock Has Paid Off Big Time For INmune Bio Inc - SETE News
Inhibrx, Inc. (NASDAQ:INBX) Short Interest Update - MarketBeat
IBRX Stock on the Rise: A Promising Investment - The InvestChronicle
Market Watch: Immuneering Corp (IMRX)’s Noteworthy Drop, Closing at 2.78 - The Dwinnex
Truist downgrades Incyte to "hold" on doubts of near-term prospects - XM
Incyte (NASDAQ:INCY) Receives Market Perform Rating from JMP Securities - Defense World
Imunon (NASDAQ:IMNN) Shares Up 5.6% - Defense World
Ratio Review: Analyzing Innovex International Inc. (INVX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Inhibrx Biosciences Inc (INBX) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):